The upregulation of MCL-1 and BCL-XL expression exhibited by the AML cells antagonizes the mechanism of action of venetoclax by binding to BIM, thus not allowing it to induce MOMP (Figure 1B). Here, BCL2L1 is linked to acute myeloid leukemia.